Vincristine News and Research

RSS
Vincristine is the active ingredient in a drug used to treat acute leukemia. It is used in combination with other drugs to treat Hodgkin disease, non-Hodgkin lymphoma, rhabdomyosarcoma, neuroblastoma, and Wilms tumor. Vincristine is also being studied in the treatment of other types of cancer. It blocks cell growth by stopping cell division. It is a type of vinca alkaloid and a type of antimitotic agent.
Study: Chemotherapy following radiation therapy improves survival in adults with low-grade gliomas

Study: Chemotherapy following radiation therapy improves survival in adults with low-grade gliomas

CASI Pharmaceuticals announces net loss of $21.5M in third quarter 2014

CASI Pharmaceuticals announces net loss of $21.5M in third quarter 2014

Eisai, Helsinn Group announce FDA approval of AKYNZEO for prevention of CINV

Eisai, Helsinn Group announce FDA approval of AKYNZEO for prevention of CINV

Study: Many HIV infected African-Americans may not be receiving effective doses of maraviroc drug

Study: Many HIV infected African-Americans may not be receiving effective doses of maraviroc drug

Merck reports results from global EMEND Phase 3 study for CINV prevention in pediatric cancer patients

Merck reports results from global EMEND Phase 3 study for CINV prevention in pediatric cancer patients

Janssen seeks expanded approval of VELCADE from EU for Mantle Cell Lymphoma

Janssen seeks expanded approval of VELCADE from EU for Mantle Cell Lymphoma

Captisol-enabled Melphalan meets primary end points in phase 2 pivotal trial

Captisol-enabled Melphalan meets primary end points in phase 2 pivotal trial

Pharmacyclics total revenue for fourth quarter 2013 increases 113% to $123.6 million

Pharmacyclics total revenue for fourth quarter 2013 increases 113% to $123.6 million

Chemotherapy following radiation therapy improves survival for adults with brain tumor

Chemotherapy following radiation therapy improves survival for adults with brain tumor

Pharmacyclics presents ibrutinib trial data for B-cell malignancies at ASH meeting

Pharmacyclics presents ibrutinib trial data for B-cell malignancies at ASH meeting

TSRI scientists find new way to boost effectiveness of anticancer drugs

TSRI scientists find new way to boost effectiveness of anticancer drugs

Apoptosis can reactivate latent herpesviruses in dying cell

Apoptosis can reactivate latent herpesviruses in dying cell

Janssen receives EC approval to use VELCADE as induction therapy in patients with multiple myeloma

Janssen receives EC approval to use VELCADE as induction therapy in patients with multiple myeloma

Spectrum Pharmaceuticals enters into agreement to acquire Talon Therapeutics

Spectrum Pharmaceuticals enters into agreement to acquire Talon Therapeutics

Researchers find a way the body can remove injured axons

Researchers find a way the body can remove injured axons

Primary mediastinal B-cell lymphoma has better outcome with more dose-intense regimens

Primary mediastinal B-cell lymphoma has better outcome with more dose-intense regimens

Children with low-risk retinoblastoma do not need postoperative chemotherapy

Children with low-risk retinoblastoma do not need postoperative chemotherapy

Millennium, Seattle Genetics commence ADCETRIS plus chemotherapy phase III trial in MTCL

Millennium, Seattle Genetics commence ADCETRIS plus chemotherapy phase III trial in MTCL

Iclusig gets FDA approval for two rare blood and bone marrow diseases

Iclusig gets FDA approval for two rare blood and bone marrow diseases

FDA approved drug to treat Ph- acute lymphoblastic leukemia

FDA approved drug to treat Ph- acute lymphoblastic leukemia